A PYMNTS Company

Takeda, Endo Face New Pay-To-Delay Suit

By  |  August 3, 2021
Takeda

The operator of Kinney Drugs retail chain sued Takeda Pharmaceutical and Endo International over claims that the pharmaceutical manufacturers allegedly engaged in a pay-to-delay scheme to keep generic versions of Takeda’s anti-constipation drug Amitiza off the market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Related: Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit

    KPH Healthcare Services’ antitrust lawsuit, filed Tuesday, August 3, in the US District Court for the District of Massachusetts, claimed that Japan-based Takeda and its US subsidiary, Takeda Pharmaceuticals USA, made “reverse payments” totaling between US$29 and US$280 million to an Endo subsidiary, Par Pharmaceuticals, to keep the generic from being introduced for over six years.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.